Newron Pharmaceuticals S.p.A.

SWX:NWRN Stock Report

Market Cap: CHF 165.2m

Newron Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of NWRN?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,076,9725.53%
Institutions1,093,0335.62%
General Public17,288,85488.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9%.

Top Shareholders

Top 20 shareholders own 11.15% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
4.93%
Tobias Scherer
960,000CHF 8.2m12.3%no data
3.08%
UBS Asset Management AG
599,762CHF 5.1m181%no data
0.63%
ZKB Asset Management
123,154CHF 1.0m1.58%no data
0.47%
Zürcher Kantonalbank, Investment Arm
91,493CHF 776.8k-8.37%0.01%
0.39%
Heights Capital Management, Inc.
75,008CHF 636.8k-90%0.14%
0.28%
Pictet Asset Management SA
53,804CHF 456.8k0%no data
0.25%
BlackRock, Inc.
48,012CHF 407.6k1.6%no data
0.22%
Ravi Anand
41,872CHF 355.5k0%no data
0.21%
Ulrich Köstlin
40,249CHF 341.7k0%no data
0.13%
Wyss & Partner AG
25,000CHF 212.3k0%0.47%
0.11%
BCV Asset Management
21,000CHF 178.3k90.9%no data
0.1%
Stefan Weber
20,351CHF 172.8k0%no data
0.062%
Patrick Langlois
12,000CHF 101.9k0%no data
0.062%
Kb - Vermögensverwaltung GmbH
12,000CHF 101.9k0%0.19%
0.059%
Knoesel & Ronge Vermögensverwaltung GmbH & Co. Kg
11,500CHF 97.6k0%0.16%
0.056%
Lombard Odier Asset Management (Switzerland) SA
10,990CHF 93.3k0%no data
0.048%
amandea Vermögensverwaltung AG
9,262CHF 78.6k0%0.22%
0.043%
Baloise Asset Management
8,429CHF 71.6k0%0.01%
0.019%
Migrosbank Asset Management
3,619CHF 30.7k0%no data
0.013%
Roberto Galli
2,500CHF 21.2k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 14:30
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Newron Pharmaceuticals S.p.A. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research